首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   6784篇
  免费   916篇
  国内免费   68篇
耳鼻咽喉   81篇
儿科学   145篇
妇产科学   187篇
基础医学   886篇
口腔科学   145篇
临床医学   591篇
内科学   1545篇
皮肤病学   350篇
神经病学   506篇
特种医学   274篇
外科学   1003篇
综合类   231篇
一般理论   2篇
预防医学   430篇
眼科学   276篇
药学   383篇
  1篇
中国医学   66篇
肿瘤学   666篇
  2023年   54篇
  2022年   78篇
  2021年   232篇
  2020年   178篇
  2019年   271篇
  2018年   280篇
  2017年   271篇
  2016年   285篇
  2015年   364篇
  2014年   401篇
  2013年   428篇
  2012年   510篇
  2011年   512篇
  2010年   337篇
  2009年   331篇
  2008年   372篇
  2007年   367篇
  2006年   347篇
  2005年   346篇
  2004年   291篇
  2003年   234篇
  2002年   244篇
  2001年   128篇
  2000年   115篇
  1999年   91篇
  1998年   50篇
  1997年   37篇
  1996年   24篇
  1995年   29篇
  1994年   31篇
  1993年   35篇
  1992年   46篇
  1991年   41篇
  1990年   39篇
  1989年   26篇
  1988年   25篇
  1987年   28篇
  1986年   27篇
  1985年   29篇
  1984年   24篇
  1983年   18篇
  1981年   11篇
  1979年   15篇
  1978年   14篇
  1977年   11篇
  1975年   9篇
  1974年   19篇
  1972年   10篇
  1971年   24篇
  1970年   9篇
排序方式: 共有7768条查询结果,搜索用时 15 毫秒
1.
2.
3.
4.
Abstract

Objective

Ras wild-type metastatic colorectal cancers (mCRC) may be treated with anti-vascular endothelial growth factor (VEGF) or anti-epidermal growth factor receptor (EGFR) agents. We aim to estimate patients’ preferences for mCRC treatment and relative importance of cost, efficacy improvement, avoidance of side effects and therapy convenience, and relative uptake between profiles that resemble Bevacizumab (anti-VEGF) and Cetuximab (anti-EGFR), two commonly prescribed mCRC targeted therapies.  相似文献   
5.
INTRODUCTIONPsoriasis is a chronic inflammatory condition that affects the skin and joints, and is associated with cardiovascular risk factors, including metabolic syndrome (MetS). We aimed to assess the prevalence of MetS in patients with psoriasis and determine whether there was a correlation between psoriasis severity and MetS in a Singapore population.METHODSThis was a cross-sectional study of patients with psoriasis, aged 18–69 years, who attended a tertiary dermatology referral centre in Singapore from October 2007 to February 2009. Fasting glucose, lipids, blood pressure, Psoriasis Area and Severity Index, and body mass index were measured. MetS was diagnosed in the presence of three or more criteria of the modified National Cholesterol Education Program Adult Treatment Panel III.RESULTSAmong 338 patients with psoriasis, there were 238 (70.4%) men and 100 (29.6%) women, who were Chinese (n = 228; 67.5%), Malay (n = 52; 15.4%) and Indian (n = 58; 17.2%). The prevalence of MetS was 45.1%. MetS was 44% more prevalent in patients older than 50 years (p = 0.02). Malay patients with psoriasis were significantly more likely to have hypertriglyceridaemia, elevated fasting plasma glucose and abdominal obesity. There was no significant correlation between psoriasis severity and risk of MetS.CONCLUSIONThe prevalence of MetS in patients with psoriasis in Singapore was 45.1%, or nearly threefold higher than the Singapore general population. Patients with psoriasis should be screened yearly for MetS and any modifiable cardiovascular risk factors should be actively controlled.  相似文献   
6.

Background

Rosacea is a chronic inflammatory skin condition whose etiology has been linked to mast cells and the antimicrobial peptide cathelicidin LL-37. Individuals with refractory disease have demonstrated clinical benefit with periodic injections of onabotulinum toxin, but the mechanism of action is unknown.

Objectives

To investigate the molecular mechanism by which botulinum toxin improves rosacea lesions.

Methods

Primary human and murine mast cells were pretreated with onabotulinum toxin A or B or control. Mast cell degranulation was evaluated by β-hexosaminidase activity. Expression of botulinum toxin receptor Sv2 was measured by qPCR. The presence of SNAP-25 and VAMP2 was established by immunofluorescence. In vivo rosacea model was established by intradermally injecting LL-37 with or without onabotulinum toxin A pretreatment. Mast cell degranulation was assessed in vivo by histologic counts. Rosacea biomarkers were analyzed by qPCR of mouse skin sections.

Results

Onabotulinum toxin A and B inhibited compound 48/80-induced degranulation of both human and murine mast cells. Expression of Sv2 was established in mouse mast cells. Onabotulinum toxin A and B increased cleaved SNAP-25 and decreased VAMP2 staining in mast cells respectively. In mice, injection of onabotulinum toxin A significantly reduced LL-37-induced skin erythema, mast cell degranulation, and mRNA expression of rosacea biomarkers.

Conclusions

These findings suggest that onabotulinum toxin reduces rosacea-associated skin inflammation by directly inhibiting mast cell degranulation. Periodic applications of onabotulinum toxin may be an effective therapy for refractory rosacea and deserves further study.  相似文献   
7.
8.
9.
10.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号